Viking Therapeutics (VKTX) Presents Data from VK0214 POC Study in X-ALD; Primary Objective Achieved
Tweet Send to a Friend
Viking Therapeutics, Inc. (Nasdaq: VKTX) announced the presentation of positive data from a proof-of-concept study of VK0214 in a mouse ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
